These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 29499279)

  • 1. A Newly Identified Impurity in Polysorbate 80, the Long-Chain Ketone 12-Tricosanone, Forms Visible Particles in a Biopharmaceutical Drug Product.
    Hampl V; Guo X; Ehrenstrasser C; Viertler M; Rayner L; Campanelli G; Schipflinger R; Thewes K; Cerreti A; Boehm S; Sonderegger C
    J Pharm Sci; 2018 Jun; 107(6):1552-1561. PubMed ID: 29499279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Comprehensive Assessment of All-Oleate Polysorbate 80: Free Fatty Acid Particle Formation, Interfacial Protection and Oxidative Degradation.
    Doshi N; Giddings J; Luis L; Wu A; Ritchie K; Liu W; Chan W; Taing R; Chu J; Sreedhara A; Kannan A; Kei P; Shieh I; Graf T; Hu M
    Pharm Res; 2021 Mar; 38(3):531-548. PubMed ID: 33713012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Free fatty acid particles in protein formulations, part 2: contribution of polysorbate raw material.
    Siska CC; Pierini CJ; Lau HR; Latypov RF; Fesinmeyer RM; Litowski JR
    J Pharm Sci; 2015 Feb; 104(2):447-56. PubMed ID: 25196966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Polysorbate 80 Hydrolysis and Oxidation on the Aggregation of a Monoclonal Antibody.
    Larson NR; Wei Y; Prajapati I; Chakraborty A; Peters B; Kalonia C; Hudak S; Choudhary S; Esfandiary R; Dhar P; Schöneich C; Middaugh CR
    J Pharm Sci; 2020 Jan; 109(1):633-639. PubMed ID: 31758949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of Polysorbate Ester Fractions and Implications in Protein Drug Product Stability.
    Tomlinson A; Zarraga IE; Demeule B
    Mol Pharm; 2020 Jul; 17(7):2345-2353. PubMed ID: 32442382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ester hydrolysis of polysorbate 80 in mAb drug product: evidence in support of the hypothesized risk after the observation of visible particulate in mAb formulations.
    Labrenz SR
    J Pharm Sci; 2014 Aug; 103(8):2268-77. PubMed ID: 24942482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polysorbate 20 Degradation in Biopharmaceutical Formulations: Quantification of Free Fatty Acids, Characterization of Particulates, and Insights into the Degradation Mechanism.
    Tomlinson A; Demeule B; Lin B; Yadav S
    Mol Pharm; 2015 Nov; 12(11):3805-15. PubMed ID: 26419339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polysorbate Degradation and Particle Formation in a High Concentration mAb: Formulation Strategies to Minimize Effect of Enzymatic Polysorbate Degradation.
    Roy I; Patel A; Kumar V; Nanda T; Assenberg R; Wuchner K; Amin K
    J Pharm Sci; 2021 Sep; 110(9):3313-3323. PubMed ID: 34077768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fatty Acids Can Induce the Formation of Proteinaceous Particles in Monoclonal Antibody Formulations.
    Zhang J; He J; Smith KJ
    J Pharm Sci; 2022 Mar; 111(3):655-662. PubMed ID: 34666046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polysorbates versus Hydroxypropyl Beta-Cyclodextrin (HPβCD): Comparative Study on Excipient Stability and Stabilization Benefits on Monoclonal Antibodies.
    Zhang H; Hong S; Tan SSK; Peng T; Goh LYH; Lam KH; Chow KT; Gokhale R
    Molecules; 2022 Oct; 27(19):. PubMed ID: 36235038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What Makes Polysorbate Functional? Impact of Polysorbate 80 Grade and Quality on IgG Stability During Mechanical Stress.
    Grabarek AD; Bozic U; Rousel J; Menzen T; Kranz W; Wuchner K; Jiskoot W; Hawe A
    J Pharm Sci; 2020 Jan; 109(1):871-880. PubMed ID: 31614127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Edetate Disodium as a Polysorbate Degradation and Monoclonal Antibody Oxidation Stabilizer.
    Yarbrough M; Hodge T; Menard D; Jerome R; Ryczek J; Moore D; Baldus P; Warne N; Ohtake S
    J Pharm Sci; 2019 Apr; 108(4):1631-1635. PubMed ID: 30502482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid Polysorbate 80 Degradation by Liver Carboxylesterase in a Monoclonal Antibody Formulated Drug Substance at Early Stage Development.
    Zhang S; Xiao H; Molden R; Qiu H; Li N
    J Pharm Sci; 2020 Nov; 109(11):3300-3307. PubMed ID: 32721471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An in-depth examination of fatty acid solubility limits in biotherapeutic protein formulations containing polysorbate 20 and polysorbate 80.
    Glücklich N; Dwivedi M; Carle S; Buske J; Mäder K; Garidel P
    Int J Pharm; 2020 Dec; 591():119934. PubMed ID: 33059015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Understanding Particle Formation: Solubility of Free Fatty Acids as Polysorbate 20 Degradation Byproducts in Therapeutic Monoclonal Antibody Formulations.
    Doshi N; Demeule B; Yadav S
    Mol Pharm; 2015 Nov; 12(11):3792-804. PubMed ID: 26419285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of Subvisible Particles in Biopharmaceutical Formulations Using Raman Spectroscopy Provides Insight into Polysorbate 20 Degradation Pathway.
    Saggu M; Liu J; Patel A
    Pharm Res; 2015 Sep; 32(9):2877-88. PubMed ID: 25773722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating a Modified High Purity Polysorbate 20 Designed to Reduce the Risk of Free Fatty Acid Particle Formation.
    Doshi N; Ritchie K; Shobha T; Giddings J; Gregoritza K; Taing R; Rumbelow S; Chu J; Tomlinson A; Kannan A; Saggu M; Cai SK; Nicoulin V; Liu W; Russell S; Luis L; Yadav S
    Pharm Res; 2021 Sep; 38(9):1563-1583. PubMed ID: 34495486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Protein Particle Formation in IgG1 mAbs Formulated with PS20 Vs. PS80 When Subjected to Interfacial Dilatational Stress.
    Vaclaw C; Merritt K; Griffin VP; Whitaker N; Gokhale M; Volkin DB; Ogunyankin MO; Dhar P
    AAPS PharmSciTech; 2023 Apr; 24(5):104. PubMed ID: 37081185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dissolution of Polysorbate 20 Degradation Related Free Fatty Acid Particles in Intravenous Bag Solutions.
    Doshi N; Rutherford K; Najjar A
    J Pharm Sci; 2021 Feb; 110(2):687-692. PubMed ID: 33039438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Free fatty acid particles in protein formulations, part 1: microspectroscopic identification.
    Cao X; Fesinmeyer RM; Pierini CJ; Siska CC; Litowski JR; Brych S; Wen ZQ; Kleemann GR
    J Pharm Sci; 2015 Feb; 104(2):433-46. PubMed ID: 25175016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.